A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor. Results: Initially, more than 50% of ...
Peptides cleaved by DPP4 may be pharmacological or physiological substrates. Physiological peptide substrates are defined as those peptides whose endogenous levels of intact to cleaved forms are ...
As a new class of OADs, DPP-4 inhibitors have many important advantages over other currently available antidiabetic drugs. Compared with currently available insulin secretagogues, DPP-4 inhibitors, by ...
The NICE Centre for Guidelines is currently conducting a partial update of NICE guideline 28 (NG28) Type 2 diabetes in adults: management. NICE is updating our recommendations on drug therapy. The ...
Researchers found that the rate difference of depression was 3.48 per 1000 person-years between GLP-1 RA users and SGLT-2i users. HealthDay News — For older adults with type 2 diabetes (T2D), use of ...
Zituvimet XR is supplied in 3 extended-release tablet strengths. The Food and Drug Administration (FDA) has approved Zituvimet XR (sitagliptin and metformin hydrochloride) extended-release tablets as ...
CSPC Pharmaceutical Group Ltd. on Jan. 13 gained the National Medical Products Administration’s approval of Shanzeping (prusogliptin tablets; DBPR-108) as a novel oral dipeptidyl peptidase-IV (DPP-4) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results